About Us

iOx Therapeutics (iOx) is a near clinical stage biotechnology company developing a series of synthetic lipid compounds to prime and boost an immune response in cancer patients by stimulating invariant natural killer T cells (iNKT). The Company’s two lead compounds, IMM60 and IMM65, are expected to enter the clinic in the next year.

Portage owns approximately 60% of iOx. Portage serves as Chief Executive Officer, Chief Scientific Officer, and provides project management and financial roles. In addition, Portage holds the Chairman and executive member seats on the Board of Directors.

Pipeline

COMPANY
ASSET
INDICATION
STAGE

Logo Iox

ASSET
IMM-601
IMM-652
INDICATION
Melanoma &
Lung Cancer
Bladder / Ovarian
STAGE
Planned Phase I/II
Planned Phase I/II
1. IMM60 is funded through a clinical trial agreement with Oxford
2. IMM65 is funded via a Horizon 2020 grant

Programs

iOx Therapeutics plans to develop a pipeline of iNKT agonists, which have been shown to inhibit the growth of tumors as a monotherapy in preclinical studies. Through the Company’s clinical trial sponsorship agreement with Oxford University, we are going to conduct both Phase 1 and Phase 2 trials for its lead product candidate, IMM60, alone and in combination with anti-PD1 antibodies. iOx’s second product candidate, IMM65, a nanoparticle co-formulation of IMM60 plus an NY-ESO-1 vaccine, received funding from the European Union’s Horizon 2020 grant program (the PRECIOUS GRANT) to cover the development, manufacturing and planned phase I/II clinical studies.

iNKT are a distinct type of immune cell that bridges the innate and adaptive immune systems. IMM60 is designed to optimally engage the T cell receptor on the iNKT, and facilitate its binding to the CD1d molecule on dendritic cells, resulting in the secretion of a large amount of cytokines. This leads to activation and expansion of important immune system components, which primes and boosts an adaptive immune attack against cancer. Preclinical studies have validated that the Company’s iNKT agonists inhibit tumor growth.

Leadership

Dr. Walters has over 20 years of leadership and expertise in oncology/immunology …

Dr. Declan Doogan has over 30 years of industry experience in both major …

Director, Member of Scientific Advisory Board

Professor Cerundolo is Professor of Immunology at the University of…

Dr. Annalisa Jenkins is a life science thought leader with over 20 years of …

Dr. Jonathan Skipper is the Executive Vice President for Technology …

Chief Scientific Officer

Robert Kramer has 24 years of experience in the pharmaceutical…

Scientific Advisory Board

Director, Member of Scientific Advisory Board

Professor Cerundolo is Professor of Immunology at the University of…

Member of Scientific Advisory Board

Dr. Wolchok is currently chief of the Melanoma and Immunotherapeutics…

Member of Scientific Advisory Board

Dr. Coukos is a tenured Professor in the Division of Gynecologic…

Member of Scientific Advisory Board

Dr. Dhodapkar is the Anise McDaniel Brock Chair and Georgia Research…